BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Pusceddu S, Rossi RE, Torchio M, Prinzi N, Niger M, Coppa J, Giacomelli L, Sacco R, Facciorusso A, Corti F, Raimondi A, Prisciandaro M, Colombo E, Beninato T, Del Vecchio M, Milione M, Di Bartolomeo M, de Braud F. Differential Diagnosis and Management of Diarrhea in Patients with Neuroendocrine Tumors. J Clin Med 2020;9:E2468. [PMID: 32752158 DOI: 10.3390/jcm9082468] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
Number Citing Articles
1 Panzuto F, Magi L, Rinzivillo M. Exocrine pancreatic insufficiency and somatostatin analogs in patients with neuroendocrine neoplasia. Expert Opin Drug Saf 2021;20:383-6. [PMID: 33530760 DOI: 10.1080/14740338.2021.1881478] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Magi L, Rinzivillo M, Panzuto F. What Gastroenterologists Should Know about Carcinoid Syndrome. Gastroenterology Insights 2022;13:127-38. [DOI: 10.3390/gastroent13010014] [Reference Citation Analysis]
3 Anthony LB, O'Dorisio TM. Opportunities to Improve Symptom Control with Somatostatin Congeners in GEP-NETs: A Review of Key Issues. Oncologist 2021;26:e1171-8. [PMID: 34097784 DOI: 10.1002/onco.13847] [Reference Citation Analysis]
4 Panzuto F. Clinical Challenges in the Management of Neuroendocrine Tumors. J Clin Med 2021;10:E257. [PMID: 33445572 DOI: 10.3390/jcm10020257] [Reference Citation Analysis]
5 Spada F, Rossi RE, Kara E, Laffi A, Massironi S, Rubino M, Grimaldi F, Bhoori S, Fazio N. Carcinoid Syndrome and Hyperinsulinemic Hypoglycemia Associated with Neuroendocrine Neoplasms: A Critical Review on Clinical and Pharmacological Management. Pharmaceuticals (Basel) 2021;14:539. [PMID: 34199977 DOI: 10.3390/ph14060539] [Reference Citation Analysis]